Skip to main content

Table 2 Incidence, mortality and utility of long term complications due to high-dose (HD) or standard-dose (SD) chemotherapy for non-seminomatous germ cell cancer.

From: A decision-analytic approach to define poor prognosis patients: a case study for non-seminomatous germ cell cancer patients

Morbidity References Incidence Suspected agent Mortality Change in mortality3 Utility4 Change in morbidity5
   SD HD      
Therapy related leukaemia [10, 22, 23] 0.5% 1.5% Etoposide (< 2 g/m2, > 2 g/m2) 70% 0.7% 0.90 0.03%
Vascular toxicity [10, 16, 24, 25]        
Raynaud's phenomenon   25% >25% Bleomycin    - -
Cardiovascular disease   7% 10% Cisplatin 10% 0.3% 0.7 0.81%
Neurotoxicity [5, 10, 21]        
Peripheral neuropathy   4% 5% Cisplatin    - -
Ototoxicity   5% 65% Cisplatin (<400 mg/m2, > 400 mg/m2)    - -
Nephrotoxicity [5, 10, 16]        
Renal failure   1% 4% Cisplatin    0.6 1.2%
Hypertension   10% 24% Cisplatin (<400 mg/m2, > 400 mg/m2)    0.99 0.14%
Gonadal toxicity [10, 16, 26, 41]        
Infertility1   50% >50% Cisplatin     
Sexual functioning2   15% 27%     0.92 0.96%
Total       1%   3.14%
  1. 1 oligospermia/azoospermia
  2. 2 sexual dissatisfaction
  3. 3 Change in mortality calculated as (incidenceHD-CT - incidenceSD-CT) × fatality
  4. 4 Utility ranges from 0–1 and is a measure of health related quality of life
  5. 5 Change in morbidity calculated as (incidenceHD-CT - incidenceSD-CT) × (1-U) × (1-fatality).